- BioTime (BTX +2.3%) subsidiary Cell Cure Neurosciences gets a $1.74M grant for 2014 from Israel's OCS.
- The funds will be used to develop OpRegen for the treatment of AMD.
- The company intends to complete preclinicals and file an IND for the commencement of human trials next year.
- Cell Cure notes that it will repay the grant plus interest via royalty payments to OCS. (PR)
at CNBC.com (Apr 8, 2014)